CoChat
Sign Up
Cited by 66Ovarian function and disordersDiabetes, Cardiovascular Risks, and LipoproteinsGestational Diabetes Research and Management

Type 2 diabetes and cardiovascular disease in polycystic ovary syndrome: what are the risks and can they be reduced?

Tomlinson, J., Millward, A., Stenhouse, E., Pinkney, J.·2010·Diabetic Medicine
DOI 10.1111/j.1464-5491.2010.02994.x
Open this paper in CoChat — free account

Abstract

Diabet. Med. 27, 498–515 (2010) Polycystic ovary syndrome (PCOS) is a risk factor for Type 2 diabetes mellitus (T2DM) and cardiovascular disease (CVD), but these risks are poorly defined. This study aimed to evaluate the evidence for these risks and whether screening and risk reduction are feasible. Medline reviews and data quality analysis were used using standard tools. Results showed that (i) polycystic ovary syndrome is a risk factor forT2DM but the magnitude of risk is uncertain, (ii) fasting plasma glucose is an inadequate screening test forT2DM in this population and the oral glucose tolerance test is superior, (iii) the identification of women with PCOS for diabetes screening is constrained by current diagnostic criteria for PCOS; however, women with oligomenorrhoea and those with diagnosed PCOS and obesity or a family history of T2DM are at highest risk, (iv) risk factors for T2DM are improved by weight loss interventions and by metformin. However, no studies have determined whether T2DM incidence is reduced, (v) polycystic ovary syndrome is associated with cardiovascular disease (CVD) risk factors but data on CVD incidence are weak, (vi) risk factors for CVD are improved by the same interventions and statins and (vi) no studies have evaluated whether CVD incidence is reduced. While PCOS has important metabolic associations, and short‐term interventions reduce risk factors for T2DM and CVD, data on prevalence and incidence of T2DM and particularly CVD are poor. There is a need for a clear definition of PCOS, for diabetes screening protocols and for long‐term studies to determine whether risks can be reduced.

Integrity signals

Registry

Crossref · 10.1111/j.1464-5491.2010.02994.x

Cites

97 of 97 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • We identified one low-quality systematic review (level I) with high risk of bias; however, this was deemed insufficient evidence on which to base the recommendation.

    “We identified one low-quality systematic review (level I) with high risk of bias; 108 however, this was deemed insufficient evidence on which to base the recommendation.”

    From Assessment and management of polycystic ovary syndrome: Summary of an evidence-based guideline (2011) · cites this paper as [108]

Cites

Flagged first, then by citations

1 of the 98 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Related

Authors
Tomlinson, J., Millward, A., Stenhouse, E., & Pinkney, J.
Affiliations
  • Royal Cornwall Hospital (GB)
  • Peninsula College of Medicine and Dentistry (GB)
  • University of Plymouth (GB)
  • Derriford Hospital (GB)
Corresponding author
Tomlinson, J.
ORCID
Venue
Diabetic Medicine
Publisher
Wiley
Published
2010-04-21
Volume
27
Issue
5
Pages
498-515
ISSN
  • 0742-3071 (ISSN-L)
  • 1464-5491
DOI
10.1111/j.1464-5491.2010.02994.x
OpenAlex
W2005958897
Cited by
66
References
98
Citations by year
2024: 3 · 2023: 2 · 2022: 2 · 2020: 3 · 2019: 4 · 2018: 5 · 2017: 5 · 2016: 2 · 2015: 7 · 2014: 7 · 2013: 6 · 2012: 11
FWCI
1.17
Type
journal article
Language
en
Open access
closed
Licence
onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations
  • Diabetic Medicine (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Obstetrics and Gynecology › Gestational Diabetes Research and Management
Keywords
polycystic ovary syndrome, type 2 diabetes, cardiovascular disease, diabetes screening, oral glucose tolerance test, fasting blood glucose, metformin, weight loss, statins, obesity, oligomenorrhea, PCOS diagnostic criteria, risk mitigation
MeSH terms
Blood Glucose, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Fasting, Female, Glucose Tolerance Test, Humans, Hypoglycemic Agents, Mass Screening, Metformin, Polycystic Ovary Syndrome, Risk Factors, Weight Loss, Incidence, Prevalence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review